Alimentary pharmacology & therapeutics · 2025
MELD 3.0 Improves Risk Stratification and Mortality Prediction in Hepatorenal Syndrome-Acute Kidney Injury: A Multicentre Study.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Jing, Chen Xinyi, Zhou Qin, Chen Jingyi, Yang Guanghong, Pan Qiaoling, Huang Chenjie, Luo Rui, Lu Xiaoqing, Chen Xiaoxiao, Li Tan, Huang Haijun, Li Lanjuan, Cao Hongcui, Yu Jiong
Аннотация
BACKGROUND: Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a life-threatening complication in decompensated cirrhosis with limited predictive tools for short-term prognosis. Traditional models such as MELD, MELD-Na and Child-Turcotte-Pugh (CTP) have notable limitations in this population.
AIMS: This study aimed to evaluate the prognostic performance of the newly developed MELD 3.0 score in predicting 90-day mortality among patients with HRS-AKI.
METHODS: In this multicentre retrospective cohort study, 539 patients with HRS-AKI were enrolled from three tertiary hospitals between 2015 and 2023. The predictive performance of MELD 3.0 for 90-day mortality was systematically compared with MELD, MELD-Na, and CTP scores through ROC curve (AUC) and net reclassification improvement (NRI) analysis.
RESULTS: MELD 3.0 demonstrated the highest predictive performance for 90-day mortality (AUC = 0.812), significantly surpassing MELD (AUC = 0.790, p = 0.006), MELD-Na (AUC = 0.791, p = 0.002) and CTP (AUC = 0.756, p = 0.005). It was an independent predictor of mortality (HR = 1.13 per point, 95% CI: 1.11-1.16, p < 0.001) and achieved significant NRI over MELD (7.05%), MELD-Na (6.01%) and CTP (13.75%). Its predictive performance remained robust across ACLF severity, age subgroups and treatment response profiles.
CONCLUSION: This is the first large-scale study to validate MELD 3.0 in HRS-AKI. By offering enhanced discrimination and clinically meaningful reclassification, MELD 3.0 provides a more refined tool for early risk stratification, with potential to guide timely intervention, inform transplant decisions and improve personalized care in this critically ill population.
AIMS: This study aimed to evaluate the prognostic performance of the newly developed MELD 3.0 score in predicting 90-day mortality among patients with HRS-AKI.
METHODS: In this multicentre retrospective cohort study, 539 patients with HRS-AKI were enrolled from three tertiary hospitals between 2015 and 2023. The predictive performance of MELD 3.0 for 90-day mortality was systematically compared with MELD, MELD-Na, and CTP scores through ROC curve (AUC) and net reclassification improvement (NRI) analysis.
RESULTS: MELD 3.0 demonstrated the highest predictive performance for 90-day mortality (AUC = 0.812), significantly surpassing MELD (AUC = 0.790, p = 0.006), MELD-Na (AUC = 0.791, p = 0.002) and CTP (AUC = 0.756, p = 0.005). It was an independent predictor of mortality (HR = 1.13 per point, 95% CI: 1.11-1.16, p < 0.001) and achieved significant NRI over MELD (7.05%), MELD-Na (6.01%) and CTP (13.75%). Its predictive performance remained robust across ACLF severity, age subgroups and treatment response profiles.
CONCLUSION: This is the first large-scale study to validate MELD 3.0 in HRS-AKI. By offering enhanced discrimination and clinically meaningful reclassification, MELD 3.0 provides a more refined tool for early risk stratification, with potential to guide timely intervention, inform transplant decisions and improve personalized care in this critically ill population.